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Rearrangements of the ALL-1/MLL1 gene underlie the majority of infant acute leukaemias, as well as of therapy-related leukaemias
developing in cancer patients treated with inhibitors of topoisomerase II, such as VP16 and doxorubicin. The rearrangements fuse
ALL-1 to any of 450 partner genes or to itself. Here, we describe the unique features of ALL-1-associated leukaemias, and recent
progress in understanding molecular mechanisms involved in the activity of the ALL-1 protein and of its Drosophila homologue
TRITHORAX.
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ACUTE LEUKAEMIAS ASSOCIATED WITH ALL-1
REARRANGEMENTS
Chromosome band 11q23 is involved in reciprocal chromosome
translocations in 5–10% of children and adults with acute
lymphoblastic leukaemia (ALL) or acute myelogeneous leukaemia
(AML). Nearly all these rearrangements affect the ALL-1 gene, also
termed MLL1, HRX and HTRX, located at 11q23. The transloca-
tions occur within an 8.3kb breakpoint cluster region of the gene
and result in the replacement of ALL-1-coding sequence 3’ to the
breakpoint by the coding sequence of the translocation partner
(Gu et al, 1992; Tkachuk et al, 1992). In a second and less frequent
type of rearrangement, ALL-1 undergoes partial tandem duplica-
tion (self-fusion), resulting in the production of a larger protein
(Schichman et al, 1995). The most common ALL-1 translocations
are t(4; 11), t(9; 11), t(11; 19), t(6; 11) and t(10; 11), accounting for
40, 27, 12, 5 and 5% of cases, respectively. However, the total
number of different loci participating in ALL-1 translocations is
amazingly high and has already exceeded 50 (Huret et al, 2001).
There is an association between particular chromosomal
translocations involving ALL-1 and subtypes of leukaemias. Thus,
t(4; 11) nearly always occurs in ALL, t(9; 11) is mostly associated
with AML, as are t(11; 19)(q23;p13.1), t(6;11), t(10;11) and the
partial duplications. t(11; 19)(q23;p13.3) occurs in both AML and
ALL. ALL1-associated ALLs are characterised as CD10
 , CD19
þ
and by B-cell precursor phenotype (pro B), with a high frequency
of myeloid-associated (CD15 and/or CD65) antigen expression.
Hence, they are also designated biphenotypic or mixed-lineage
leukaemia. The AMLs are usually of the myelomonocytic (FAB-
M4) or monoblastic (FAB-M5) morphological subtypes and
sometimes express cell-surface lymphoid markers. The prognosis
of patients with 11q23 abnormalities is dismal. Age is an important
prognostic factor. Thus, less than 25% of infants (o1 year) and
adults older than 40 or 50 years, with t(4; 11) or t(9; 11), are cured.
Patients of intermediate age, in particular 2–9 or 1–14 years old,
have significantly better prognosis (Johansson et al, 1998; Swans-
bury et al, 1998; Pui et al, 2002).
The hallmark of ALL1-associated leukaemias is their epidemiol-
ogy (reviewed in Greaves, 1999; Biondi et al, 2000). They
predominate infant acute leukaemia (80% of ALL and 65% of
AML), and account for the majority of therapy-related (secondary)
leukaemias developing in 5–15% of primary cancer patients who
had received intensive chemotherapy, including epipodophyllo-
toxins (VP16) and anthracyclines (doxorubicin) (Pui and Relling,
2000). These drugs are inhibitors of topoisomerase II, and act by
stabilising double-strand DNA breaks generated by this enzyme. In
both infant and secondary leukaemias, the latency period is
remarkably brief. In infants, ALL-1 rearrangements can be already
detected in utero and the average age at diagnosis is 6 months, and
in secondary leukaemias, latency averages around 18–30 months
(reviewed in Greaves, 1999; Pui and Relling, 2000). The very brief
time between the initiating event and clinical disease, in
conjunction with the high rate of concordance in identical twins
with infant leukaemia, points to the effectiveness of ALL-1 fusion
proteins in driving the initial clone into frank leukaemia. Based on
the findings from therapy-related leukaemia, it was hypothesised
(Ross et al, 1994) that transplacental exposure of the foetus to
natural substances that inhibit topoisomerase II (such as
flavonoids in foods and drinks) might play a role in infant
leukaemia. Such exposure will induce accumulation of DNA’s
free ends from within the breakpoint cluster region of ALL-1,
and this would eventually result in 11q23 translocations. The
results of recent biochemical experiments (Strick et al, 2000)
are consistent with this hypothesis. A structural feature shared
by many topoisomerase II inhibitors, including anticancer drugs,
is the quinone moiety. The metabolism of quinones is controlled
by the enzyme NQO1 that converts toxic benzoquinones to
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www.bjcancer.comhydroxyquinones. A polymorphism in nucleotide 609 of the
enzyme substitutes a proline into serine and consequently
inactivates the enzyme. Comparison of paediatric leukaemias with
and without ALL-1 rearrangement indicated significant bias in the
former for NQO1 genotypes conferring low or no enzymatic
activity (Wiemels et al, 1999; Smith et al, 2002), suggesting that
inactivating NQO1 polymorphism increases the risk for ALL-1-
associated leukaemias.
MOUSE MODELS OF ALL-1 LEUKAEMOGENESIS
Two methodologies have been used to generate mouse models of
ALL-1 leukaemogenesis. Knockin of the partner gene AF9 into the
ALL-1 locus by homologous recombination resulted in animals
that developed AML at approximately 6 months (Dobson et al,
1999). Transmission of the transgene in the germ line and its
expression during embryogenesis resulted in viable progeny. This,
together with the observation that mice carrying a single null allele
of ALL-1 were not predisposed to AML (Corral et al, 1996), rules
out a model of leukaemogenesis due to haploinsufficiency (passive
loss of function). Rather, an extensive series of investigations
applying retro viral transduction into cultured haematopoietic
progenitor cells, followed by transplantation into mice, have
established that ALL-1 fusion genes act as dominant alleles and the
disease is due to ALL-1 gain of function. Structure–function
analysis of several ALL-1 fusion proteins showed that particular
elements within the partner proteins, such as transcription effector
domains and protein–protein interaction motifs, are critical for
the leukaemogenic activity (reviewed in Ayton and Cleary, 2001).
The presence of dimerisation domains in some of the partner
proteins, such as AF6, AF10, AF17, AF1p, GAS7 and AF3p21
suggested that self-association might underlie the role of the
partner proteins with such motifs in the leukaemogenicity of ALL-
1 fusion proteins. The most compelling experimental evidence for
this is that homodimerisation of ALL-1 by synthetic dimerisation
modules mimics many of the features of ALL-1 fusion proteins
(Dobson et al, 2000; So et al, 2003b, Martin et al, 2003). Also,
disruption of the dimerisation motifs in some partner proteins
eliminated pathogenicity. Although self-dimerisation appears to
play a key role in leukaemogenesis associated with partner
proteins containing a dimerisation motif, the most common
fusions–ALL-1/AF4, ALL-1/AF9 and ALL-1/ENL–do not dimerise.
Both the knockin and retroviral transduction approaches turned
out to be biased towards myeloid leukaemia. However, very recent
studies with virally transduced ALL1-ENL (Zeisig et al, 2003) and
ALL1-GAS7 (So et al, 2003a) showed transformation of bipheno-
typic lymphoid/myeloid cells and induction of biphenotypic
leukaemia. So et al serially plated the transduced bone marrows
in methylcellulose and found that the fusion protein conferred
long-term growth capacity to multipotential progenitors. The
progenitors spontaneously differentiated into biphenotypic and
myeloid progenitors during culturing in vitro. Moreover, mice
injected with the transduced serially-plated progenitors developed
either biphenotypic leukaemia, or AML or ALL. On the basis of
these experiments, it was proposed that ALL-1 fusion proteins
enhance the self-renewal potential of multipotent progenitors that
retain an ability to differentiate into downstream progeny. The
latter are more susceptible to differentiation blocking by ALL-1
fusion proteins, or are prone to secondary mutations required for
full malignant transformation.
GENE EXPRESSION PROFILES OF ALL-1 LEUKAEMIAS
DNA microarrays technology has been recently applied to
construct expression profiles of ALLs and/or AMLs with ALL-1
rearrangements (Rozovskaia et al, 2001, 2003; Armstrong et al,
2002; Yeoh et al, 2002). Both ALL-1-associated ALLs and AMLs
have distinct expression patterns that distinguish them from other
types of ALL and AML, respectively. The distinction is more robust
for ALL, probably reflecting the unusual clinical and biological
features and the biphenotypic trait of the disease, not shared
by other classes of ALL. In one study (Rozovskaia et al, 2003),
genes whose expression pattern separated ALLs with t(4;11) from
other ALLs were further subdivided, enabling the identification of
two subfamilies of t(4;11) tumours. In that study, a substantial
number of the genes, which were found to correlate in their
expression with the t(4;11) genotype, had been previously
associated with cancer, apoptosis or growth control. These
included overexpressed oncogenes (such as HOX A9, HOX A10,
MEIS1, LMO2 and MYC), overexpressed genes involved in
protection from apoptosis and in survival, underexpressed
proapoptotic genes, overexpressed genes involved in drug
resistance and underexpressed tumour suppressors and growth
inhibitors such as FHIT and DAPK1.
Determination of which of the genes pointed out in the DNA
microarrays analyses plays a direct role in pathogenesis might
come from experiments with mice. One approach will be to alter
the expression (e.g. by interference RNA) of a suspected gene in
cell lines with 11q23 translocations, and examine whether the
capacity of the cell lines to induce leukaemia in mice is lost. The
second approach will be to transduce the fusion genes into mice
null for genes suspected of playing an essential role in ALL-1
pathogenesis, and examine the effect on leukaemia development.
Such an experiment has been recently reported for HOX A9 and
HOX A7 (Ayton and Cleary, 2003). These two genes were found
required for in vitro myeloid immortalisation by the MLL/ENL
fusion protein transduced by a retroviral vector into bone marrow
cells. Further, HOX A9 was found to be indispensable for ALL-1-
dependent leukaemogenesis in vivo. Applying a complementary
approach, Kumar et al (2004) bred mice to obtain animals
transgenic for MLL-AF9 and null for HOX A9 and examined
leukaemia development. Surprisingly, the absence of HOX A9 did
not affect the incidence and latency of leukaemia, although the
malignant cells displayed a more immature myeloid phenotype.
The authors suggest that several HOX genes might have to be
inactivated to impair leukaemogenicity. The reasons for the
contrasting conclusion obtained by the two approaches are
currently not known.
BIOLOGICAL AND BIOCHEMICAL ACTIVITY OF
ALL-1 AND ITS DROSOPHILA HOMOLOGUE
TRITHORAX (TRX)
ALL-1 and TRX are members of the evolutionary conserved gene
family termed as the Trx group (TrxG) that are positive regulators
of the homeotic gene complex (HOX) during development, and
whose activity is opposed by the repressive activity of the
Polycomb group (PcG). The TrxG and PcG proteins are not
required for initiation of HOX genes activity, but act to maintain
transcriptional states through later stages of development (re-
viewed in Brock and van Lohuizen, 2001; Simon and Tamkun,
2002). ALL-1 also acts at the stage of maintenance (Yu et al, 1998).
Since considerably more genetic and biological information is
available about TRX, in comparison to ALL-1, here we will
emphasise studies of the former. Approximately 20 genes have
been characterised as members of the fly TrxG; however, this
number is rapidly growing based on genetic and molecular criteria
(Gildea et al, 2000; Faucheux et al, 2003). Further, it has became
apparent that the target genes of the TrxG are not limited to HOX
genes (Kuzin et al, 1994; Maurange and Paro, 2002; Beltran et al,
2003). In this context, we have recently demonstrated (Smith et al,
2004) that following heat induction, the TRX complex is quickly
recruited to several heat-shock genes on salivary polytene
chromosomes, where it is required to maintain a high level of
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TRX in HOX gene expression.
Much effort was devoted to in vivo analysis of the properties of
TrxG and PcG response elements (TRE and PRE, respectively) at
target loci in Drosophila. The emerging picture of the best studied
target, the regulatory region of the Drosophila Bithorax complex
BX-C gene Ubx, suggests that although TREs and PREs are
intermingled within a 1.5kb region bxd, they may represent
separable regulatory elements (Tillib et al, 1999). It is still not clear
whether the TrxG and PcG proteins occupy their respective
responsive elements at all time, or only when the target gene is
active or repressed, respectively. Evidence that these proteins may
occupy their binding sites depending on the status of gene
expression came recently from analysis of Drosophila larval fat
body (Marchetti et al, 2003). BX-C genes are repressed in the
anterior region of the fat body, but are active in the mid-posterior
part. In parallel, the PC protein (but not TRX) was detected at the
cytological site of bithorax on polytene chromosomes from
the anterior part of the fat body, while a strong signal of
TRX (but not of PC) was detected on chromosomes from the
mid-posterior fat body.
The mechanism by which TRX and ALL-1 reach their target loci
is not known. The absence of sequence-specific DNA-binding
protein among components of the TRX and ALL-1 complexes (see
later) emphasises this quandary. Several recent studies (Bender
and Fitzgerald, 2002; Hogga and Karch, 2002; Rank et al, 2002)
showed that ectopic or induced transcription through regulatory
elements of the Bithorax complex switches the elements from
silenced to activated states. On the basis of this, it was proposed
that passage of the RNA polymerase II complex through a
regulatory element displaces the repressive PcG complex, set there
by default, and enables recruitment of the TRX complex that
imprints epigenetic marks instructing transcription of the adjacent
HOX gene.
Chromatin immunoprecipitation (ChIP) experiments previously
identified TRX both on TREs and on promoters within the
Bithorax gene complex (Orlando et al, 1998). The ChIP
methodology was recently applied to ALL-1 (Nakamura et al,
2002; Milne et al, 2002) and the protein was found bound at the
promoters of HOX A9 and HOX C8 in cultured cells expressing
these genes (homologues of Drosophila TREs and PREs have not
been identified yet in mammals). Elimination of ALL-1, by
applying interference RNA methodology, blocked transcription
of HOX A9. Both studies showed that ALL-1 is a histone
methyltransferase that methylates lysine 4 of histone H3. The
enzymatic activity is conferred by the C-terminal SET domain. The
presence of ALL-1 on the promoters of the two HOX genes is
linked to H3-Lys4 methylation as well as to acetylation of histones
H3 and H4 at the promoter. Several other TrxG, PcG, and other
chromatin – associated proteins containing SET domains – were
recently shown to methylate histones at specific residues (reviewed
in Orlando, 2003). Such marking of histones (as are acetylation,
phosphorylation and ubiquitination of specific histone residues)
conveys heritable transcription patterns (expression or silencing)
in an epigenetic manner.
The molecular mechanisms by which TRX and ALL-1 act was
further elucidated by the identification and characterisation of
stable protein complexes associated with the two proteins. TRX is a
component of the TAC1 complex that includes the histone
acetyltransferase (HAT) dCBP, and a SET - binding factor, SBF1
(Petruk et al, 2001). The recruitment of TAC1 components to the
HSP70 locus following heat induction results in enhanced
expression of the gene and correlates with acetylation and
methylation of histones (Smith et al, 2004). The ALL-1 complex
(Nakamura et al, 2002) completely varies from that of TRX. It
contains at least 29 proteins. The majority of the latter are
components of seven subcomplexes involved in transcription
preinitiation, nucleosome remodelling, histone deacetylation,
histone methylation or RNA processing. The purified ALL-1
complex methylates, acetylates, deacetylates and remodels nucleo-
somes and is bound at the promoter of the target gene HOX A9.I t
appears that a major role of ALL-1 is to assemble this large
supercomplex of enzymatic activities. In summary, the recent
biochemical experiments indicate that TRX and ALL-1 recruit to
target genes a host of enzymatic activities, mostly involved in
epigenetic marking. The way in which these marks are inherited to
progeny cells (memorized) is not known (they have to survive
DNA replication, during which the histones are thought to be
stripped off the DNA), but it has been speculated (Turner, 2000;
Richards and Elgin, 2002) that the modified histones stay at or
near the replication fork and are incorporated into the daughter
DNA strands.
UNRESOLVED ISSUES AND FUTURE DIRECTIONS
While considerable progress was made in identification of the
biochemical activities of the ALL-1 and TRX protein complexes,
the mechanism by which these complexes are recruited to specific
sequences (genes) is completely unknown. The recent reports that
transcription of regulatory regions induces heritable transcrip-
tional activation of the Drosophila BX-C genes raises the
possibility that such a mechanism is involved in the recruitment
of TRX and ALL-1 complexes. Another outstanding issue is the
identification of genes, other than HOX, that are regulated by ALL-
1 and TRX. The demonstration that the mammalian PcG protein
BMI-1 regulates the important cell cycle locus INK4a/ARF (Jacobs
et al, 1999) suggests that looking for additional ALL-1/TRX targets
(e.g. by conditional elimination or activation of the two proteins,
followed by DNA microarray analysis) might be rewarding.
Further, the process by which the ALL-1-mediated histone H3-
Lys4 methylation induces chromatin alteration (presumably
decondensation) and gene expression, and the precise roles of
the transcriptional subcomplexes within ALL-1 supercomplex,
have yet to be determined. A new line of investigation is likely to
originate from the recent remarkable finding that the PHD finger
motif of the ING2 protein binds phosphoinositides, and that this
interaction regulates the biological activity of the latter (Gozani
et al, 2003). The presence of four PHD finger motifs in both ALL-1
and TRX points to a potential central mechanism by which these
proteins are regulated. Finally, the reason why ALL-1 (and
presumably TRX) is proteolytically cleaved by an evolutionary
conserved enzyme into two polypeptides, which are held together,
is not known (Nakamura et al, 2002; Yokoyama et al, 2002; Hsieh
et al, 2003).
Mouse models have recently identified the type of precursor cell
transformed by ALL-1 fusion proteins, and DNA microarrays
analyses focused attention on genes that might play a direct role in
leukaemogenesis. Identification of such genes is clearly a focal
point for understanding the disease in molecular terms and for
future therapeutic intervention. However, other central questions
remain. First, do all ALL-1 fusions, including self-fusions, trigger a
single pathway leading to disease? Why are most fusions associated
with specific leukaemia subtype (e.g. ALL1-AF4 with ALL, ALL1-
AF6 with AML)? Second, since the fusion proteins lack the SET
domain with its histone H3-Lys4 methylation activity, how do they
retain transcriptional activation capacity? Do they target all genes
regulated by normal ALL-1? Do they compete with normal ALL-1
on the same targets? Do they block transcription of some loci?
Also, the absence of the PHD fingers in ALL-1 fusion proteins
should relieve them from potential regulation by phosphoinosi-
tides; whether this is an important aspect of the leukaemogenic
activity of these proteins has yet to be determined. A third issue is
whether ALL-1 fusions confer resistance to apoptosis. ALL-1-
associated leukaemias are notorious for their poor prognosis with
chemotherapy, and exhibit drug resistance. Since it is now believed
ALL-1/MLL1 and acute leukaemia
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activation of apoptotic pathways, drug resistance of ALL-1 leukaemias
might be due to disruption of apoptotic processes. Such disruptions
appear to be crucial for the development of many tumours (reviewed
in Johnstone et al, 2002). Still, very little has been reported about this
issue with regard to ALL-1 leukaemias. In one study (Kersey et al,
1998), ALLs with t(4; 11) were compared to similar tumours without
t(4; 11) and found to be dramatically more resistant to serum
deprivation stress. A recent investigation (Wiederschain et al, 2003)
showed nuclear colocalisation of the fusion protein ALL1-ELL with
p53, and loss of p53-mediated apoptosis. Whether this phenomenon
is unique to that particular fusion protein or is it of a more general
nature is presently not known.
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